Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 5/20 | 1.00 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 1.00 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 1.00 |
| ▸ | KMT2A | Q03164 | 9/20 | 0.54 |
| ▸ | CTDSP1 | Q9GZU7 | 2/20 | 0.54 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.53 |
| ▸ | GLA | P06280 | 1/20 | 0.53 |
| ▸ | MEN1 | O00255 | 7/20 | 0.53 |
| ▸ | HPGD | P15428 | 2/20 | 0.51 |
| ▸ | POLB | P06746 | 3/20 | 0.51 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.51 |
| ▸ | CASP3 | P42574 | 3/20 | 0.50 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.49 |
| ▸ | GPR55 | Q9Y2T6 | 1/20 | 0.48 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6260508 | 0.82 | KDM4E (0.68) | KDM4ESMN1; SMN2HSD17B10KMT2ACTDSP1 | |
| SCHEMBL13256671 | 0.74 | KDM4E (0.62) | KDM4ESMN1; SMN2HSD17B10KMT2ACTDSP1 | |
| SCHEMBL5838218 | 0.74 | ALDH1A1 (0.69) | KDM4ESMN1; SMN2HSD17B10KMT2ACTDSP1 | |
| SCHEMBL22079528 | 0.72 | KMT2A (0.71) | KDM4ESMN1; SMN2HSD17B10KMT2ACTDSP1 | |
| SCHEMBL4462900 | 0.72 | KDM4E (0.66) | KDM4EHSD17B10KMT2ACTDSP1ALDH1A1 | |
| SCHEMBL26695993 | 0.71 | KDM4E (0.65) | KDM4ESMN1; SMN2HSD17B10KMT2ACTDSP1 | |
| SCHEMBL6260912 | 0.70 | KDM4E (1.00) | KDM4ESMN1; SMN2HSD17B10KMT2ACTDSP1 | |
| SCHEMBL6260500 | 0.69 | KMT2A (1.00) | SMN1; SMN2KMT2ACTDSP1ALDH1A1MEN1 | |
| SCHEMBL5947099 | 0.69 | KDM4E (0.71) | KDM4ESMN1; SMN2KMT2AALDH1A1GLA | |
| SCHEMBL195372 | 0.69 | KDM4E (0.61) | KDM4ESMN1; SMN2HSD17B10KMT2ACTDSP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050182061-A1 | Phthalimide compounds useful as protein kinase inhibitors | GREEN JEREMY (US) | 2005-08-18 | — | — | US | claimed |
| WO-2005039564-A1 | PHTHALIMIDE COMPOUNDS USEFUL AS PROTEIN KINASE INHIBITORS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2005-05-06 | — | — | WO | claimed |
| US-20050182061-A1 | Phthalimide compounds useful as protein kinase inhibitors | GREEN JEREMY (US) | 2005-08-18 | — | — | US | disclosed |
| US-20050159599-A1 | Cyclic compound, process for producing the same, and pest control agent | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2005-07-21 | — | — | US | disclosed |
| WO-2005039564-A1 | PHTHALIMIDE COMPOUNDS USEFUL AS PROTEIN KINASE INHIBITORS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2005-05-06 | — | — | WO | disclosed |
| EP-1481972-A1 | CYCLIC COMPOUND, PROCESS FOR PRODUCING THE SAME, AND PEST CONTROL AGENT | Sumitomo Chemical Takeda Agro Company, Limited (JP) | 2004-12-01 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050182061-A1 | Phthalimide compounds useful as protein kinase inhibitors | PDK1, PDPK1, MTOR | KDM4E 793/4885SMN1; SMN2 969/4885HSD17B10 2659/4885 |
| US-20050159599-A1 | Cyclic compound, process for producing the same, and pest control agent | CNPY2, CNPY3, HAX1 | KDM4E 594/4885SMN1; SMN2 4544/4885HSD17B10 564/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.